Loading
A phase 2 trial of TY-9591 and Osimertinib in non-small-cell lung cancer and brain and spinal cord tumours, run by TYK Medicines, Inc, now recruiting.
TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases is a phase 2 interventional study registered as NCT05948813 by TYK Medicines, Inc, with 420 participants planned, started 2023-08-17 and due to reach its primary completion in 2025-12-15. Interventions recorded: TY-9591 and Osimertinib.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares TYK Medicines and the tag pipeline.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Brain metastases (secondary brain tumours), Brain and spinal cord tumours (all types) and the tag pipeline.
Shares Brain metastases (secondary brain tumours), Brain and spinal cord tumours (all types) and the tag pipeline.
Shares TY-9591, TYK Medicines, EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer.